Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30370095 | 0.97 | ALDH1A1 (0.47) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL11363902 | 0.79 | ALOX15 (0.55) | KDM4EALDH1A1ALOX15BCHEPTGS2 | |
| SCHEMBL28312413 | 0.78 | ALOX15 (0.54) | KDM4EALDH1A1ALOX15BCHEPTGS2 | |
| SCHEMBL1780894 | 0.78 | KDM4E (0.51) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL5059395 | 0.78 | PTGS1 (0.55) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL1476459 | 0.76 | KDM4E (0.52) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| 4,4-Diantipyrylmethane Monohydrate SCHEMBL3879841 | 0.76 | ALOX15 (0.62) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| 4,4-Diantipyrylmethane Monohydrate SCHEMBL8664775 | 0.74 | ALOX15 (0.60) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL4324895 | 0.74 | ALOX15 (0.60) | HSD17B10KDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL28442475 | 0.74 | KDM4E (0.69) | HSD17B10KDM4EALDH1A1ALOX15BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330436-A1 | Compositions and Methods for Treatment and Prevention of Pyrexia in Horses | KINDRED BIOSCIENCES, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10682337-B2 | Compositions and methods for treatment and prevention of pyrexia in horses | KINDRED BIOSCIENCES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180071256-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF PYREXIA IN HORSES | KINDRED BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9192594-B2 | Ophthalmic solution for protecting internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique | Sanseverino, Renato (IT) | 2015-11-24 | — | — | US | disclosed |
| EP-2459186-B1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | TROISI SALVATORE (IT) | 2013-10-09 | — | — | EP | disclosed |
| CN-102470120-A | Ophthalmic solutions for protecting the internal structure of the eyeball against ultraviolet rays or for treating keratoconus with a transepithelial cross-linking technique | SANSEVERINO RENATO | 2012-05-23 | — | — | CN | disclosed |
| US-20120121567-A1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | TROISI, SALVATORE (IT) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330436-A1 | Compositions and Methods for Treatment and Prevention of Pyrexia in Horses | XDH, COX15, TTPA | HSD17B10 2107/4885KDM4E 4485/4885ALDH1A1 604/4885 |
| US-20120121567-A1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | MMP2, MMP9, MMP26 | HSD17B10 2209/4885KDM4E 2720/4885ALDH1A1 1138/4885 |
| US-20180071256-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF PYREXIA IN HORSES | XDH, COX15, TTPA | HSD17B10 2107/4885KDM4E 4485/4885ALDH1A1 604/4885 |
| US-10682337-B2 | Compositions and methods for treatment and prevention of pyrexia in horses | XDH, COX15, TTPA | HSD17B10 2107/4885KDM4E 4485/4885ALDH1A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.